Traduction de «Administer radiotherapy to patients » (Anglais → Français) :

administer radiotherapy to patients | manage patients undertaking radiotherapy | administer radiotherapy | supervise patients undertaking radiography

administer anaesthetics to wounded people | administer anesthesia to patients | administer anaesthetics to patients | provide local, regional or general anaesthetic to patients

assess patients while they are on treatment | review patients on radiotherapy treatment | perform 'on treatment' reviews | perform on-treatment review

complications of medical devices correct drug properly administered in therapeutic or prophylactic dosage as the cause of any adverse effect misadventures to patients during surgical and medical care surgical and medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

64xddd The person in charge of a hospital must not permit a targeted substance to be sold, provided or administered to a patient or animal under treatment as an in-patient or an out-patient of the hospital except pursuant to a prescription or other authorization of a practitioner practising in the hospital.

64. The person in charge of a hospital must not permit a targeted substance to be sold, provided or administered to a patient or animal under treatment as an in-patient or an out-patient of the hospital except pursuant to a prescription or other authorization of a practitioner practising in the hospital.

(Return tabled) Question No. 286 Mr. Alex Atamanenko: With regard to the horse slaughter industry in Canada: (a) does the government know whether third party monitoring of video footage is occurring at Viandes Richelieu and Bouvry Exports and, if so, (i) what is the monitoring criteria, (ii) who is monitoring the footage, (iii) what actions, if any, have been taken as a result of observations, (iv) is footage monitoring to be a daily practice at this and other Canadian horse slaughter plants, (v) how many hours have been monitored, (vi) is footage archived and for how long, (vii) does the recording continuously loop over previous footage; (b) which tissue types and/or bodily fluids are targeted by the government when testing for phenylbuta ...[+++]zone and other drugs in horsemeat, (i) what percentage of drug testing is performed on equine organs (particularly kidney and liver) as opposed to other tissues, such as muscle, (ii) what is the exact methodology and what are the specific testing mechanisms used to detect phenylbutazone and other drugs in horsemeat; (c) what surveys or studies has the government undertaken or relied on to determine the number of overall horse owners and keepers that have administered to horses under their care, even once in the horse's lifetime, substances that are banned for human consumption, in (i) Canada, (ii) the United States (US); (d) what surveys or studies encompassing the overall horse population has the government undertaken or relied on to determine the percentage of veterinarians who routinely administer to horse patients under their care, at any time in the horse's lifetime, substances that are banned for use in food animals, in (i) Canada, (ii) the US; (e) what was the ratio between the number of horses and the number of prescriptions of substances banned for use in food animals at any time in their lifetime, issued by veterinarians to the overall horse population in (i) Canada, (ii) the US; (f) what were the results of European ...

(o) safety features making it possible to ascertain identification, authenticity and traceability of medicinal products subject to medical prescription as defined in Title VI, other than radiopharmaceuticals and medicinal products which due to their specific characteristics are not suitable for distribution through a wholesaler and pharmacy and therefore are sold directly by the producer to a clinical establishment where they are directly administered to the patient; safety features may be applied, on the basis of a case-by-case analysis, to non-prescription medicinal products where the risk related to the product indicates, on the basi ...[+++]s of the criteria set out in Article 54a(4), that there are reasonable grounds for considering that the product may be falsified.